Skip to main content
Emily (Stamell) Ruiz, MD, Dermatology, Boston, MA

EmilyStamell(Stamell)RuizMD

Dermatology • Boston, MA

Physician

Join to view full profile

Dr. Ruiz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Ruiz's full profile

Already have an account?

  • Office

    450 Brookline Ave

    Boston, MA 02215
    Phone+1 617-732-5500

Education & Training

  • Montefiore Medical Center/Albert Einstein College of Medicine
    Montefiore Medical Center/Albert Einstein College of MedicineResidency, Dermatology, 2011 - 2014
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineInternship, Internal Medicine, 2010 - 2011
  • New York University School of Medicine
    New York University School of MedicineClass of 2010

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2014 - 2025
  • NY State Medical License
    NY State Medical License 2011 - 2015
  • American Board of Dermatology Dermatology

Publications & Presentations

PubMed

Lectures

  • High Yield ""Power Hour"" for Residents 
    American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019
  • National cancer expenditure analysis in the United States Medicare population, 2013. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • FDA Approves Cosibelimab-Ipdl for Advanced Cutaneous Squamous Cell Carcinoma
    FDA Approves Cosibelimab-Ipdl for Advanced Cutaneous Squamous Cell CarcinomaDecember 17th, 2024
  • Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
    Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b TumorsOctober 20th, 2024
  • Study Confirms the Ability of Castle Biosciences’ DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
    Study Confirms the Ability of Castle Biosciences’ DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell CarcinomaSeptember 5th, 2024
  • Join now to see all

Dr. Emily Ruiz, Dr. Emily Ruiz, MD, Dr. E Ruiz, Dr. Emily Stamell Ruiz